Explore the vast range of titles available.

The boreal forest, one of the largest biomes on Earth, provides ecosystem services that benefit society at levels ranging from local to global. Currently, about two-thirds of the area covered by this biome is under some form of management, mostly for wood production. Services such as climate regulation are also provided by both the unmanaged and managed boreal forests. Although most of the boreal forests have retained the resilience to cope with current disturbances, projected environmental changes of unprecedented speed and amplitude pose a substantial threat to their health. Management options to reduce these threats are available and could be implemented, but economic incentives and a greater focus on the boreal biome in international fora are needed to support further adaptation and mitigation actions.

Photon-mediated coupling between distant matter qubits may enable secure communication over long distances, the implementation of distributed quantum computing schemes, and the exploration of new regimes of many-body quantum dynamics. Solid-state quantum emitters coupled to nanophotonic devices represent a promising approach towards these goals, as they combine strong light-matter interaction and high photon collection efficiencies. However, nanostructured environments introduce mismatch and diffusion in optical transition frequencies of emitters, making reliable photon-mediated entanglement generation infeasible. Here we address this long-standing challenge by employing silicon-vacancy color centers embedded in electromechanically deflectable nanophotonic waveguides. This electromechanical strain control enables control and stabilization of optical resonance between two silicon-vacancy centers on the hour timescale. Using this platform, we observe the signature of an entangled, superradiant state arising from quantum interference between two spatially separated emitters in a waveguide. This demonstration and the developed platform constitute a crucial step towards a scalable quantum network with solid-state quantum emitters.

18 F-fluoroethoxybenzovesamicol (FEOBV) is a new PET radiotracer that binds to the vesicular acetylcholine transporter. In both animals and healthy humans, FEOBV was found sensitive and reliable to characterize presynaptic cholinergic nerve terminals in the brain. It has been used here for we believe the first time in patients with Alzheimer’s disease (AD) to quantify brain cholinergic losses. The sample included 12 participants evenly divided in healthy subjects and patients with AD, all assessed with the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) cognitive scales. Every participant underwent three consecutive PET imaging sessions with (1) the FEOBV as a tracer of the cholinergic terminals, (2) the 18 F-NAV4694 (NAV) as an amyloid-beta tracer, and (3) the 18 F-Fluorodeoxyglucose (FDG) as a brain metabolism agent. Standardized uptake value ratios (SUVRs) were computed for each tracer, and compared between the two groups using voxel wise t-tests. Correlations were also computed between each tracer and the cognitive scales, as well as between FEOBV and the two other radiotracers. Results showed major reductions of FEOBV uptake in multiple cortical areas that were evident in each AD subject, and in the AD group as a whole when compared to the control group. FDG and NAV were also able to distinguish the two groups, but with lower sensitivity than FEOBV. FEOBV uptake values were positively correlated with FDG in numerous cortical areas, and negatively correlated with NAV in some restricted areas. The MMSE and MoCA cognitive scales were found to correlate significantly with FEOBV and with FDG, but not with NAV. We concluded that PET imaging with FEOBV is more sensitive than either FDG or NAV to distinguish AD patients from control subjects, and may be useful to quantify disease severity. FEOBV can be used to assess cholinergic degeneration in human, and may represent an excellent biomarker for AD.

This study was designed to test the interaction between amyloid-β and tau proteins as a determinant of metabolic decline in preclinical Alzheimer’s disease (AD). We assessed 120 cognitively normal individuals with [ 18 F]florbetapir positron emission tomography (PET) and cerebrospinal fluid (CSF) measurements at baseline, as well as [ 18 F]fluorodeoxyglucose ([ 18 F]FDG) PET at baseline and at 24 months. A voxel-based interaction model was built to test the associations between continuous measurements of CSF biomarkers, [ 18 F]florbetapir and [ 18 F]FDG standardized uptake value ratios (SUVR). We found that the synergistic interaction between [ 18 F]florbetapir SUVR and CSF phosphorylated tau (p-tau) measurements, rather than the sum of their independent effects, was associated with a 24-month metabolic decline in basal and mesial temporal, orbitofrontal, and anterior and posterior cingulate cortices ( P <0.001). In contrast, interactions using CSF amyloid-β 1–42 and total tau biomarkers did not associate with metabolic decline over a time frame of 24 months. The interaction found in this study further support the framework that amyloid-β and hyperphosphorylated tau aggregates synergistically interact to cause downstream AD neurodegeneration. In fact, the regions displaying the metabolic decline reported here were confined to brain networks affected early by amyloid-β plaques and neurofibrillary tangles. Preventive clinical trials may benefit from using a combination of amyloid-β PET and p-tau biomarkers to enrich study populations of cognitively normal subjects with a high probability of disease progression in studies, using [ 18 F]FDG as a biomarker of efficacy.

9/11 Fiction, Empathy, and Otherness analyzes recent works of fiction whose principal subject is the attacks of September 11, 2001.The readings of the novels question and assess the validity and potential effectiveness of both the subsequent calls for a cosmopolitan outlook and the related, but no less significant, emphasis placed on empathy, and.

The article describes the development of the web-based Canadian Forest Service climate change indicator system, referred to as the Forest Change Tracking System. This indicator system was established in 2011 with financial support from the Adaptation theme of the Government of Canada Clean Air Agenda. The objectives of the Forest Change Tracking System are to (a) raise awareness and inform on the occurrence and scope of ongoing changes across Canadian forests associated with climate change and to (b) support the inclusion of adaptation into forest management planning and forest-related policies. The development strategy was to focus on a limited number of most relevant indicators and to build on existing capacity in order to produce information on current and future climate change impacts across Canada’s vast forests. An initial list of 141 potential indicators relevant to forestry was compiled through a series of workshops with more than 100 researchers and forest sector stakeholders and through a global scan of climate change indicator initiatives. A rating system based on each indicator’s potential relevance, sensitivity, and feasibility of measurement was used to select a subset of 35 indicators. These indicators fall within three broad systems—climate, forest, and human. Each indicator web page contains information on the relevance of the indicator, graphs, or maps on past trends and future projections across Canada and related links and references. This paper also presents lessons learned, discusses challenges and opportunities, and reviews potential next steps related to the broadening of this indicator system.

Hepatic steatosis may develop as a consequence of several dysfunctions. An increased circulating non-esterified fatty acid (NEFA) pool seems to be a major determinant in the pathogenesis of non-alcoholic fatty liver disease. Increased activation of the transcription factor sterol-regulatory-element-binding protein-1c, which promotes fatty acid synthesis, also contributes to hepatic fat accumulation. Increased hepatic fat oxidation with hepatic steatosis may be triggered by increased hepatic fat concentrations through the action of hepatic peroxisomes mediated by peroxisome proliferator-activated receptor alpha. Finally, inhibition in very low density lipoprotein secretion may also result in hepatic steatosis. This appears to be mainly controlled by the esterification of NEFAs into triacylglycerols by diacyglycerol acyltransferase-1 and -2 and the microsomal transfer protein. Physical exercise would interfere with the development of hepatic steatosis by stimulating lipid oxidation and inhibiting lipid synthesis in liver through the activation of the AMP-activated protein kinase pathway.

Background: Neuropsychiatric symptoms (NPS) affect almost all patients with dementia and are a major focus of study and treatment. Accurate assessment of NPS through valid, sensitive and reliable measures is crucial. Although current NPS measures have many strengths, they also have some limitations (e.g. acquisition of data is limited to informants or caregivers as respondents, limited depth of items specific to moderate dementia). Therefore, we developed a revised version of the NPI, known as the NPI-C. The NPI-C includes expanded domains and items, and a clinician-rating methodology. This study evaluated the reliability and convergent validity of the NPI-C at ten international sites (seven languages). Methods: Face validity for 78 new items was obtained through a Delphi panel. A total of 128 dyads (caregivers/patients) from three severity categories of dementia (mild = 58, moderate = 49, severe = 21) were interviewed separately by two trained raters using two rating methods: the original NPI interview and a clinician-rated method. Rater 1 also administered four additional, established measures: the Apathy Evaluation Scale, the Brief Psychiatric Rating Scale, the Cohen-Mansfield Agitation Index, and the Cornell Scale for Depression in Dementia. Intraclass correlations were used to determine inter-rater reliability. Pearson correlations between the four relevant NPI-C domains and their corresponding outside measures were used for convergent validity. Results: Inter-rater reliability was strong for most items. Convergent validity was moderate (apathy and agitation) to strong (hallucinations and delusions; agitation and aberrant vocalization; and depression) for clinician ratings in NPI-C domains. Conclusion: Overall, the NPI-C shows promise as a versatile tool which can accurately measure NPS and which uses a uniform scale system to facilitate data comparisons across studies.

We present a tentative review of compressibility effects in Rayleigh–Taylor instability-induced flows. The linear, nonlinear and turbulent regimes are considered. We first make the classical distinction between the static compressibility or stratification, and the dynamic compressibility owing to the finite speed of sound. We then discuss the quasi-incompressible limits of the Navier–Stokes equations (i.e. the low-Mach number, anelastic and Boussinesq approximations). We also review some results about stratified compressible flows for which instability criteria have been derived rigorously. Two types of modes, convective and acoustic, are possible in these flows. Linear stability results for perfect fluids obtained from an analytical approach, as well as viscous fluid results obtained from numerical approaches, are also reviewed. In the turbulent regime, we introduce Chandrasekhar's observation that the largest structures in the density fluctuations are determined by the initial conditions. The effects of compressibility obtained by numerical simulations in both the nonlinear and turbulent regimes are discussed. The modifications made to statistical models of fully developed turbulence in order to account for compressibility effects are also treated briefly. We also point out the analogy with turbulent compressible Kelvin–Helmholtz mixing layers and we suggest some lines for further investigations.

The management of severe Alzheimer disease often presents difficult choices for clinicians and families. The disease is characterized by a need for full-time care and assistance with basic activities of daily living. We outline an evidence-based approach for these choices based on recommendations from the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. We developed evidence-based guidelines using systematic literature searches, with specific criteria for the selection and quality assessment of articles, and a clear and transparent decision-making process. We selected articles published from January 1996 to December 2005 that dealt with the management of severe Alzheimer disease. Subsequent to the conference, we searched for additional articles published from January 2006 to March 2008 using the same search terms. We graded the strength of the evidence using the criteria of the Canadian Task Force on Preventive Health Care. We identified 940 articles, of which 838 were selected for further study. Thirty-four articles were judged to be of at least good or fair quality and were used to generate 17 recommendations. Assessment of severe Alzheimer disease should include the measurement of cognitive function and the assessment of behaviour, function, medical status, nutrition, safety and caregiver status. Management could include treatment with a cholinesterase inhibitor or memantine, or both. Treatment of neuropsychiatric symptoms begins with nonpharmacologic approaches to addressing behavioural problems. Severe agitation, aggression and psychosis, which are potentially dangerous to the patient, the caregiver and others in the environment, can be treated with atypical antipsychotics, with consideration of their increased risk of cerebrovascular events and death. All pharmacologic approaches require careful monitoring and periodic reassessment to determine whether continued treatment is necessary. Caregiver support and use of community resources are essential. Severe Alzheimer disease requires frequent monitoring by health professionals. Simple nonpharmacologic approaches may address problems with mood and agitation. Antipsychotic drug therapy is occasionally necessary despite the inherent risks. Therapy with a cholinesterase inhibitor and memantine may be useful for selected patients.